Trial Profile
Phase III clinical trial of TO-203 - Evaluation of efficacy and safety in pediatric patients with HDM-induced allergic rhinitis -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- Sponsors Torii Pharmaceutical
- 25 Jul 2018 Results published in the Allergy
- 16 Feb 2018 According to a ALK-Abello media release, based on the data from this trial Japanese Ministry of Health, Labour and Welfare,has approved to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients.
- 24 Mar 2017 According to a company media release, ALK announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has submitted an application to the Japanese Ministry of Health, Labour and Welfare, seeking to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients. The new application is based on results from this trial.